EA201890225A1 - Слитые белки, которые связываются с fc рецепторами человека - Google Patents

Слитые белки, которые связываются с fc рецепторами человека

Info

Publication number
EA201890225A1
EA201890225A1 EA201890225A EA201890225A EA201890225A1 EA 201890225 A1 EA201890225 A1 EA 201890225A1 EA 201890225 A EA201890225 A EA 201890225A EA 201890225 A EA201890225 A EA 201890225A EA 201890225 A1 EA201890225 A1 EA 201890225A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptors
human
proteins
slip
binding
Prior art date
Application number
EA201890225A
Other languages
English (en)
Russian (ru)
Inventor
Роберт Энтони Гриффин
Дэвид Пол Хамфриз
Ширли Джейн Питерс
Original Assignee
Юсб Биофарма Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Биофарма Спрл filed Critical Юсб Биофарма Спрл
Publication of EA201890225A1 publication Critical patent/EA201890225A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA201890225A 2015-07-06 2016-07-06 Слитые белки, которые связываются с fc рецепторами человека EA201890225A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1511787.2A GB201511787D0 (en) 2015-07-06 2015-07-06 Proteins
PCT/EP2016/065914 WO2017005767A1 (en) 2015-07-06 2016-07-06 Fusion proteins which bind to human fc receptors

Publications (1)

Publication Number Publication Date
EA201890225A1 true EA201890225A1 (ru) 2018-06-29

Family

ID=54013529

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890225A EA201890225A1 (ru) 2015-07-06 2016-07-06 Слитые белки, которые связываются с fc рецепторами человека

Country Status (10)

Country Link
US (1) US20180194856A1 (cg-RX-API-DMAC10.html)
EP (1) EP3319991A1 (cg-RX-API-DMAC10.html)
JP (1) JP7097293B2 (cg-RX-API-DMAC10.html)
CN (1) CN108473571B (cg-RX-API-DMAC10.html)
AU (1) AU2016290523B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017028331A2 (cg-RX-API-DMAC10.html)
CA (1) CA2991363A1 (cg-RX-API-DMAC10.html)
EA (1) EA201890225A1 (cg-RX-API-DMAC10.html)
GB (1) GB201511787D0 (cg-RX-API-DMAC10.html)
WO (1) WO2017005767A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106068274A (zh) 2014-03-05 2016-11-02 Ucb生物制药私人有限公司 多聚体Fc蛋白
IL309260B2 (en) 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
KR20190032392A (ko) 2016-07-22 2019-03-27 글리크닉 인코포레이티드 향상된 fc 수용체 결합을 갖는 규칙적으로 다량체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
BR112019009495A2 (pt) 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
JP7351835B2 (ja) * 2017-12-14 2023-09-27 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 視神経脊髄炎の処置のための組換えIgG Fc多量体
AU2019235513B2 (en) * 2018-03-16 2026-01-29 Liverpool School Of Tropical Medicine Chimeric Fc receptor binding proteins and uses thereof
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业(上海)股份有限公司 一种cdc平台抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147326A1 (en) * 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DE10001372A1 (de) * 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
GB0922209D0 (en) * 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
CA2888519C (en) * 2012-10-17 2023-02-21 Liverpool School Of Tropical Medicine Immunomodulatory proteins
CN106068274A (zh) * 2014-03-05 2016-11-02 Ucb生物制药私人有限公司 多聚体Fc蛋白
CN106132994A (zh) * 2014-03-05 2016-11-16 Ucb生物制药私人有限公司 多聚体Fc蛋白
CA2978501A1 (en) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics

Also Published As

Publication number Publication date
JP2018519834A (ja) 2018-07-26
JP7097293B2 (ja) 2022-07-07
CN108473571A (zh) 2018-08-31
BR112017028331A2 (pt) 2018-09-11
US20180194856A1 (en) 2018-07-12
EP3319991A1 (en) 2018-05-16
GB201511787D0 (en) 2015-08-19
WO2017005767A1 (en) 2017-01-12
AU2016290523A1 (en) 2018-01-18
CN108473571B (zh) 2022-04-15
CA2991363A1 (en) 2017-01-12
AU2016290523B2 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
PH12018501882A1 (en) Binding proteins and methods of use thereof
MX2016010953A (es) Proteinas de fc multimericas.
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201791485A1 (ru) Анти-cd47-антитела и их применения
GEP201706794B (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
MX2016014647A (es) Proteinas de fusion del ligando de ox40 (ox40l) y sus usos.
EA201591762A1 (ru) Человеческие антитела к grem1
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
UY36021A (es) Proteìnas fc multimèricas
BR112017028331A2 (pt) proteínas de fusão que se ligam a receptores fc humanos
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
DK3828204T3 (da) Fusionsproteiner af humane proteinfragmenter til at skabe ordnede multimeriserede immunoglobulin-FC-sammensætninger med forbedret komplementbinding
WO2014145016A3 (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
MX2017001038A (es) Variantes de proteina de unión al factor h y metodos de uso de estas.
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201591898A1 (ru) Антитела, направленные на m-csf